BioSpace News Archive

Cardiovascular Systems, Inc. announced today the start of enrollment in a first in-human trial of the coronary everolimus drug-coated balloon (DCB) being developed by Chansu Vascular Technologies, LLC (CVT).

Ryvu Therapeutics announced today that it will present new data during the 63rd American Society of Hematology Annual Meeting & Exposition, being held on December 11 – December 14, 2021, in Atlanta and at the 44th Annual San Antonio Breast Cancer Symposium (SABCS) being held on December 7 – December 10, 2021.

Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021

The National Kidney Foundation, the leading kidney patient organization in the U.S., applauds the Centers for Medicare and Medicaid Services for protecting dialysis patients.

Otsuka Medical Devices Co., Ltd., a fully owned subsidiary of Otsuka Holdings Co., Ltd., and its subsidiary ReCor Medical, Inc. announced the presentation of 6-month results from the RADIANCE-HTN TRIO study, a randomized sham-controlled trial in patients with resistant hypertension.

Novartis today announced that a Phase II study of investigational iptacopan (LNP023) – a first-in-class, oral, selective factor B inhibitor – in patients with C3 glomerulopathy (C3G) met primary endpoints in both patient cohorts1.

Spirovant Sciences today presented SP-101, an investigational novel recombinant adeno-associated virus (AAV) gene therapy selected for its tropism to human airway epithelia, at the 2021 North American Cystic Fibrosis Conference

ACTICOR BIOTECH today announces that the U.S Food and Drug Administration (FDA) has provided clearance for the initiation of a clinical trial in US with glenzocimab, a novel humanized monoclonal antibody fragment, for use in patients with acute ischemic stroke.

Gemini Bioproducts, LLC announced today that it has secured financing from BroadOak Capital Partners, LLC

XORTX Therapeutics Inc. wishes to clarify that the Company’s common shares were halted on both the TSX Venture Exchange (the “ TSXV ”) and the Canadian Securities Exchange (the “ CSE ”) to finalize the de-listing procedures required on the CSE.